Options: Hide MedDRA Preferred Terms
Information about indications was extracted from the indications and usage sections of the labels.
| Indication | Labels | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
| Cardiac failure congestive | x | x | x | ||||||||||||||
| Cerebral artery embolism | x | x | x | ||||||||||||||
| Cerebrovascular accident | x | x | x | x | x | x | x | x | x | x | |||||||
| Clotting | x | x | x | ||||||||||||||
| Embolism | x | x | x | x | x | ||||||||||||
| Genetic polymorphism | x | ||||||||||||||||
| Haemorrhage | x | ||||||||||||||||
| Hepatic function abnormal | x | ||||||||||||||||
| Hepatic impairment | x | ||||||||||||||||
| Increased anticoagulant effect | x | ||||||||||||||||
| Myocardial infarction | x | x | x | x | x | x | x | x | x | x | x | ||||||
| Pulmonary embolism | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
| Renal failure | x | ||||||||||||||||
| Renal impairment | x | ||||||||||||||||
| Thromboembolic event | x | x | x | x | x | x | |||||||||||
| Thromboembolism | x | ||||||||||||||||
| Thrombophlebitis | x | x | x | ||||||||||||||
| Thrombosis | x | ||||||||||||||||
| Venous thrombosis | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
standard – alternative
| 100% | ||
| 75% | ||
| 50% | ||
| 10% | ||
| frequent (1% to 100%) | ||
| infrequent (0.1% to 1%) | ||
| rare (<0.1%) | ||
| postmarketing | ||
| 0% | ||
| no frequency information | ||
| not found on label |